Drug Search Results
More Filters [+]

AMX-500

Alternative Names: AMX-500, AMX 500, AMX500, SAR-446329, SAR 446329, SAR446329
Latest Update: 2024-09-04
Latest Update Note: News Article

Product Description

Mechanisms of Action: CD3 Inhibitor,PSMA Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AMX-500

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TCD17896

P2

Recruiting

Prostate Cancer

2027-09-29

49%

Recent News Events